"Identifying and Addressing Nutrient Deficiencies while following the Specific Carbohydrate Diet"
"The Interplay Between IBD, the Gut Microbiome and SCD"
Dr. Arjomand is a scientist and entrepreneur with a successful 20 year track record developing, leading and growing scalable programs and impactful ventures across multiple health sectors. He is the Founder and CEO of Modulla Health, a GI focused nutrition clinic serving patients living with IBD or other chronic GI conditions. Dr. Arjomand is a fervent champion of diet-based interventions, especially the Specific Carbohydrate Diet (SCD), which ultimately reversed his own long-standing severe Crohn’s disease. Aside from supporting IBD patients with SCD education and implementation, Dr. Arjomand also collects SCD clinical and outcomes data for presentation and publication within the medical communities to support wider acceptance of SCD.
Prior to launching Modulla Health, Dr. Arjomand led the innovation commercialization team at the Center for Infectious Disease Research (part of Seattle Children’s Hospital) where innovative research created powerful treatments for deadly diseases affecting millions of children in developing countries. Prior to that, Dr. Arjomand was Director of Innovation and Scientific Affairs for Bill Gates’ Global Good Fund where he led numerous projects and high-profile activities with key stakeholders in all sectors of global health and development. Previously, Dr. Arjomand founded and led Accium BioSciences where he commercialized technologies he developed in his PhD dissertation. This particle accelerator mass spectrometry technology, licensed from the U.S. Department of Energy, enabled Dr. Arjomand to design and analyze samples collected from 45 Phase 1 first-in-human clinical studies sponsored by Merck, GSK, Novartis, Takeda and other global pharmaceutical companies. Dr. Arjomand conducted his own research programs, serving as co-Principal Investigator on NIH-funded clinical studies to evaluate accelerator mass spectrometry biomarkers in cancer patients (glioblastoma and acute myelocytic leukemia).
Dr. Arjomand holds a Ph.D. in Nutrition and B.S. in Genetics, both from the University of California, Davis.
Copyright ©2018-2022 Specific Carbohydrate Diet Association, Inc - All Rights Reserved.
Specific Carbohydrate Diet®, SCD®, Breaking the Vicious Cycle® are trademarks owned by Kirkton Press, Limited and licensed to Specific Carbohydrate Diet Association, Inc. to use.